{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T15:06:44Z","timestamp":1776956804008,"version":"3.51.4"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Miriam and Sheldon G. Adelson Medical Research Foundation"},{"name":"NIDA Division of Drug Supply and Analytical Services"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Brain Research"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1016\/j.brainres.2019.146410","type":"journal-article","created":{"date-parts":[[2019,8,27]],"date-time":"2019-08-27T15:08:29Z","timestamp":1566918509000},"page":"146410","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Clinically utilized kappa-opioid receptor agonist nalfurafine combined with low-dose naltrexone prevents alcohol relapse-like drinking in male and female mice"],"prefix":"10.1016","volume":"1724","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5545-5681","authenticated-orcid":false,"given":"Yan","family":"Zhou","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary Jeanne","family":"Kreek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.brainres.2019.146410_b0005","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1111\/acer.13406","article-title":"Role of the dynorphin\/kappa opioid receptor system in the motivational effects of ethanol","volume":"41","author":"Anderson","year":"2017","journal-title":"Alcohol. Clin. Exp. Res."},{"key":"10.1016\/j.brainres.2019.146410_b0010","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1038\/sj.npp.1300811","article-title":"Nalmefene induced elevation in serum prolactin in normal human volunteers: partial kappa opioid agonist activity?","volume":"30","author":"Bart","year":"2005","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.brainres.2019.146410_b0015","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.15288\/jsa.1981.42.1013","article-title":"Effects of voluntary short-term abstinence from alcohol on subsequent drinking patterns of college students","volume":"42","author":"Burish","year":"1981","journal-title":"J. Stud. Alcohol"},{"key":"10.1016\/j.brainres.2019.146410_b0020","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1038\/s41386-018-0015-y","article-title":"Preclinical evaluation of the kappa-opioid receptor antagonist CERC-501 as a candidate therapeutic for alcohol use disorders","volume":"43","author":"Domi","year":"2018","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.brainres.2019.146410_b0025","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.neuropharm.2006.04.005","article-title":"Kappa-opioid receptor modulation of accumbal dopamine concentration during operant ethanol self-administration","volume":"51","author":"Doyon","year":"2006","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.brainres.2019.146410_b0030","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2019.00471","article-title":"Drinking levels and profiles of alcohol addicted rats predict response to nalmefene","volume":"10","author":"Foo","year":"2019","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.brainres.2019.146410_b0035","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1002\/brb3.222","article-title":"The role of kappa opioid receptors in stress-induced reinstatement of alcohol seeking in rats","volume":"4","author":"Funk","year":"2014","journal-title":"Brain Behav"},{"key":"10.1016\/j.brainres.2019.146410_b0040","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1038\/sj.npp.1300175","article-title":"Effects of naltrexone alone and in combination with acamprosate on alcohol deprivation effect in rats","volume":"28","author":"Heyser","year":"2003","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.brainres.2019.146410_b0045","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s002130000601","article-title":"Kappa-opioid receptors and relapse-like drinking in long-term ethanol-experienced rats","volume":"153","author":"Holter","year":"2000","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.brainres.2019.146410_b0050","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1111\/j.1530-0277.2011.01545.x","article-title":"Persistent escalation of alcohol drinking in C57BL\/6J mice with intermittent access to 20% alcohol","volume":"35","author":"Hwa","year":"2011","journal-title":"Alcohol. Clin. Exp. Res."},{"key":"10.1016\/j.brainres.2019.146410_b0055","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s00210-008-0358-8","article-title":"Comparison of the diuretic effects of chemically diverse kappa opioid agonists in rats: nalfurafine, U50,488H, and salvinorin A","volume":"379","author":"Inan","year":"2009","journal-title":"Naunyn. Schmiedebergs Arch. Pharmacol."},{"key":"10.1016\/j.brainres.2019.146410_b0060","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0178991","article-title":"Long-term efficacy and safety of nalfurafine hydrochloride on pruritus in chronic liver disease patients: Patient-reported outcome-based analyses","volume":"12","author":"Kamimura","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.brainres.2019.146410_b0065","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/j.biopsych.2013.03.014","article-title":"The one-two punch of alcoholism: role of central amygdala dynorphin\/kappa-opioid receptors","volume":"75","author":"Kissler","year":"2014","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.brainres.2019.146410_b0070","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1176\/appi.ajp.2007.05030503","article-title":"Stress, dysregulation of drug reward pathways, and the transition to drug dependence","volume":"164","author":"Koob","year":"2007","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.brainres.2019.146410_b0075","doi-asserted-by":"crossref","first-page":"9","DOI":"10.2147\/IJNRD.S145720","article-title":"Post-marketing surveillance study of the safety and efficacy of nalfurafine hydrochloride (Remitch\u00ae capsules 2.5 \u03bcg) in 3,762 hemodialysis patients with intractable pruritus","volume":"11","author":"Kozono","year":"2018","journal-title":"Int. J. Nephrol. Renovasc. Dis."},{"key":"10.1016\/j.brainres.2019.146410_b0080","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1159\/000341268","article-title":"Efficacy and safety of a novel \u0138-agonist for managing intractable pruritus in dialysis patients","volume":"36","author":"Kumagai","year":"2012","journal-title":"Am. J. Nephrol."},{"key":"10.1016\/j.brainres.2019.146410_b0085","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.physbeh.2007.05.039","article-title":"Ethanol alters the effect of kappa receptor ligands on dopamine release in the nucleus accumbens","volume":"92","author":"Lindholm","year":"2007","journal-title":"Physiol. Behav."},{"key":"10.1016\/j.brainres.2019.146410_b0090","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1038\/s41386-018-0155-0","article-title":"Phosphoproteomic approach for agonist-specific signaling in mouse brains: mTOR pathway is involved in \u03ba opioid aversion","volume":"44","author":"Liu","year":"2019","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.brainres.2019.146410_b0095","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.alcohol.2009.05.001","article-title":"Blockade of ethanol reward by the kappa opioid receptor agonist U50,488","volume":"43","author":"Logrip","year":"2009","journal-title":"Alcohol"},{"key":"10.1016\/j.brainres.2019.146410_b0100","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1016\/j.euroneuro.2016.10.008","article-title":"Nalmefene for the management of alcohol dependence: review on its pharmacology, mechanism of action and meta-analysis on its clinical efficacy","volume":"26","author":"Mann","year":"2016","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.brainres.2019.146410_b0105","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1111\/j.1530-0277.1994.tb00098.x","article-title":"A double-blind, placebo-controlled pilot study to evaluate the efficacy and safety of oral nalmefene HCl for alcohol dependence","volume":"18","author":"Mason","year":"1994","journal-title":"Alcohol. Clin. Exp. Res."},{"key":"10.1016\/j.brainres.2019.146410_b0110","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1007\/s00213-005-0067-7","article-title":"A single injection of the kappa opioid antagonist norbinaltorphimine increases ethanol consumption in rats","volume":"182","author":"Mitchell","year":"2005","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.brainres.2019.146410_b0115","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s00213-002-1028-z","article-title":"Effects of a newly synthesized kappa-opioid receptor agonist, TRK-820, on the discriminative stimulus and rewarding effects of cocaine in rats","volume":"161","author":"Mori","year":"2002","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.brainres.2019.146410_b0120","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1001\/archpsyc.1992.01820110045007","article-title":"Naltrexone and coping skills therapy for alcohol dependence: a controlled study","volume":"49","author":"O\u2019Malley","year":"1992","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.brainres.2019.146410_b0125","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s002130100919","article-title":"Naltrexone decreases craving and alcohol self-administration in alcohol-dependent subjects and activates the hypothalamic-pituitary-adrenocortical axis","volume":"160","author":"O\u2019Malley","year":"2002","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.brainres.2019.146410_b0130","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1002\/ejp.766","article-title":"An evidence-based review of systemic treatments for itch","volume":"20","author":"Pongcharoen","year":"2016","journal-title":"Eur. J. Pain"},{"key":"10.1016\/j.brainres.2019.146410_b0135","doi-asserted-by":"crossref","first-page":"E1216","DOI":"10.3390\/ijms17081216","article-title":"Distinct effects of nalmefene on dopamine uptake rates and kappa opioid receptor activity in the nucleus accumbens following chronic intermittent ethanol exposure","volume":"17","author":"Rose","year":"2016","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.brainres.2019.146410_b0140","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0304-3940(99)00675-8","article-title":"Downregulation of kappa opioid receptor mRNA levels by chronic ethanol and repetitive cocaine in rat ventral tegmentum and nucleus accumbens","volume":"275","author":"Rosin","year":"1999","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.brainres.2019.146410_b0145","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.cellsig.2017.01.016","article-title":"Nalfurafine is a G-protein biased agonist having significantly greater bias at the human than rodent form of the kappa opioid receptor","volume":"32","author":"Schattauer","year":"2017","journal-title":"Cell. Signal."},{"key":"10.1016\/j.brainres.2019.146410_b0150","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1111\/j.1530-0277.1998.tb03931.x","article-title":"Nalmefene causes greater hypothalamic-pituitary-adrenal axis activation than naloxone in normal volunteers: implications for the treatment of alcoholism","volume":"22","author":"Schluger","year":"1998","journal-title":"Alcohol. Clin. Exp. Res."},{"key":"10.1016\/j.brainres.2019.146410_b0155","first-page":"249","article-title":"Nalfurafine hydrochloride to treat pruritus: a review","volume":"8","author":"Shigeki","year":"2015","journal-title":"Clin. Cosm. Investig. Dermatol."},{"key":"10.1016\/j.brainres.2019.146410_b0160","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.brainres.2003.09.057","article-title":"Effect of repeated administration of TRK-820 (nalfurafine), a kappa-opioid receptor agonist, on tolerance to its antinociceptive and sedative actions","volume":"995","author":"Suzuki","year":"2004","journal-title":"Brain Res."},{"key":"10.1016\/j.brainres.2019.146410_b0165","doi-asserted-by":"crossref","first-page":"PL353-358","DOI":"10.1016\/S0024-3205(00)00582-8","article-title":"A novel kappa-opioid receptor agonist, TRK-820, blocks the development of physical dependence on morphine in mice","volume":"66","author":"Tsuji","year":"2000","journal-title":"Life Sci"},{"key":"10.1016\/j.brainres.2019.146410_b0170","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.alcohol.2014.03.002","article-title":"The alcohol deprivation effect model for studying relapse behavior: a comparison between rats and mice","volume":"48","author":"Vengeliene","year":"2014","journal-title":"Alcohol"},{"key":"10.1016\/j.brainres.2019.146410_b0175","doi-asserted-by":"crossref","first-page":"2539","DOI":"10.1038\/s41386-018-0199-1","article-title":"PET imaging reveals lower kappa opioid receptor availability in alcoholics but no effect of age","volume":"43","author":"Vijay","year":"2018","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.brainres.2019.146410_b0180","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1038\/sj.npp.1301438","article-title":"Pharmacological evidence for a motivational role of kappa-opioid systems in ethanol dependence","volume":"33","author":"Walker","year":"2008","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.brainres.2019.146410_b0185","doi-asserted-by":"crossref","first-page":"2955","DOI":"10.1007\/s00213-017-4691-9","article-title":"Blockade of alcohol escalation and \u201crelapse\u201d drinking by pharmacological FAAH inhibition in male and female C57BL\/6J mice","volume":"234","author":"Zhou","year":"2017","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.brainres.2019.146410_b0190","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.neulet.2018.02.056","article-title":"Effects of mesyl salvinorin B alone and in combination with naltrexone on alcohol deprivation effect in male and female mice","volume":"673","author":"Zhou","year":"2018","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.brainres.2019.146410_b0195","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1124\/jpet.117.245621","article-title":"Involvement of activated brain stress responsive systems in excessive and \u201crelapse\u201d alcohol drinking in rodent models: implications for therapeutics","volume":"366","author":"Zhou","year":"2018","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.brainres.2019.146410_b0200","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1111\/acer.14033","article-title":"Combination of human kappa opioid receptor agonist nalfurafine with low-dose naltrexone reduces excessive alcohol drinking in male and female mice","volume":"43","author":"Zhou","year":"2019","journal-title":"Alcohol. Clin. Exp. Res."}],"container-title":["Brain Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006899319304640?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006899319304640?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,9,19]],"date-time":"2023-09-19T13:17:50Z","timestamp":1695129470000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006899319304640"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":40,"alternative-id":["S0006899319304640"],"URL":"https:\/\/doi.org\/10.1016\/j.brainres.2019.146410","relation":{},"ISSN":["0006-8993"],"issn-type":[{"value":"0006-8993","type":"print"}],"subject":[],"published":{"date-parts":[[2019,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinically utilized kappa-opioid receptor agonist nalfurafine combined with low-dose naltrexone prevents alcohol relapse-like drinking in male and female mice","name":"articletitle","label":"Article Title"},{"value":"Brain Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.brainres.2019.146410","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"146410"}}